Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.

Autor: Cornelisse VJ; Kirketon Road Centre, NSW Health, Sydney, NSW, Australia; and The Kirby Institute, University of NSW, Sydney, NSW, Australia; and Monash University, Melbourne, Vic., Australia., Kearley JJM; Kirketon Road Centre, NSW Health, Sydney, NSW, Australia., Vargas Castillo J; Kirketon Road Centre, NSW Health, Sydney, NSW, Australia., Macharg L; Queenstown Medical Centre, Queenstown, Aotearoa, New Zealand., McLaughlin VA; Te Whatu Ora Southern, National Public Health Service, Aotearoa, New Zealand., Jack SJ; Te Whatu Ora Southern, National Public Health Service, Aotearoa, New Zealand., Swift C; Public Health Unit, South Eastern Sydney Local Health District, Sydney, NSW, Australia.
Jazyk: angličtina
Zdroj: Sexual health [Sex Health] 2023 Dec; Vol. 20 (6), pp. 585-587.
DOI: 10.1071/SH23139
Abstrakt: Background: In August 2022, in response to a global mpox outbreak, the World Health Organization recommended the Vaccinia vaccination for at-risk people.
Methods: Case study.
Results: We describe a case of a HIV-negative bisexual man who developed a symptomatic mpox infection 13weeks after completing a two-dose course of subcutaneous third-generation modified vaccinia Ankara vaccines. The case likely acquired his mpox infection in the USA; was diagnosed in Aotearoa, New Zealand; and was followed-up in Australia, as he was actively travelling during his infection.
Conclusions: This case highlights the importance of maintaining clinical suspicion for mpox in people who present with consistent symptoms, even if they are fully vaccinated. Also, as he travelled around Aotearoa, New Zealand, and Australia during his infection, this case highlights how public health authorities and clinicians can cooperate across jurisdictional boundaries to support cases and minimise the risk of onward transmission.
Databáze: MEDLINE
Externí odkaz: